View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
TUESDAY, Aug. 4 (HealthDay News) -- The United Kingdom should not accept new proposals from the European Commission that would allow drug companies to provide information about prescription-only drugs over the Internet and in some print publications, according to an editorial published in the August issue of the Drug and Therapeutics Bulletin.
Timed to coincide with an August public consultation on the issue conducted by the United Kingdom's Medicines and Healthcare products Regulatory Agency, the editorial warns about the difficulties of distinguishing between the provision of non-promotional information and direct-to-consumer advertising, which would still be prohibited in the European Union. It also cites lax regulation of direct-to-consumer advertising in the United States.
The editorial states concerns that acceptance of the European Commission's proposals would result in promotional information about prescription drugs being presented to the public even though it would be billed as being purely informational. It also raises the concern that the regulatory bodies may not be able to effectively police the dissemination of information.
"There is a need for independent, reliable information to enable people to make informed choices about treatment," the authors write. "However, pharmaceutical companies' inherent conflict of interest means it is naive to expect them ever to provide such information."
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top